Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.49 |
| ▸ | ACP1 | P24666 | 5/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.49 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | DUSP26 | Q9BV47 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17295261 | 0.83 | S1PR1 (0.57) | MEN1ALDH1A1KMT2AS1PR1S1PR3 | |
| SCHEMBL17295262 | 0.83 | S1PR1 (0.57) | MEN1ALDH1A1KMT2AS1PR1S1PR3 | |
| SCHEMBL17302130 | 0.83 | S1PR1 (0.57) | MEN1ALDH1A1KMT2AS1PR1S1PR3 | |
| SCHEMBL29726497 | 0.81 | FAAH (0.63) | MEN1ALDH1A1KMT2AS1PR1S1PR3 | |
| SCHEMBL17302144 | 0.81 | FAAH (0.63) | MEN1ALDH1A1KMT2AS1PR1S1PR3 | |
| SCHEMBL22420194 | 0.81 | FAAH (0.64) | MEN1ALDH1A1KMT2AS1PR1S1PR3 | |
| SCHEMBL17295234 | 0.80 | S1PR1 (0.67) | MEN1ALDH1A1KMT2AS1PR1S1PR3 | |
| SCHEMBL17295236 | 0.80 | S1PR1 (0.67) | MEN1ALDH1A1KMT2AS1PR1S1PR3 | |
| SCHEMBL17295627 | 0.80 | FAAH (0.75) | MEN1ALDH1A1KMT2AS1PR1S1PR3 | |
| SCHEMBL17295629 | 0.80 | FAAH (0.75) | MEN1ALDH1A1KMT2AS1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197952-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | UNIVERSITAT BERN (CH) | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197952-A1 | THIAZOLIDINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION | GRIN2B, IL1B, GRIA4 | MEN1 4464/4885ALDH1A1 186/4885KMT2A 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.